Understanding cannabidiol: current evidence, availability and access pathways
On-demand recorded 24 Feb 2021
The RACGP NSW&ACT has partnered with the NSW Ministry of Health on this webinar about recent developments in relation to cannabidiol, including registration of Epidyolex®, and their implications for practice. The webinar will also provide an overview of the evidence for the use of cannabidiol in treatment of certain conditions and the appropriate circumstances for compounding cannabis based medicines.
- Describe the evidence for the use of cannabidiol in Lennox-Gastaut syndrome, Dravet syndrome and Tuberous Sclerosis Complex, and the approved indication for Epidyolex®
- Describe the evidence for the use of cannabidiol, and where off-label use of Epidyolex® might have sufficient evidence
- Describe appropriate circumstances for compounding of medicines, and specifically for cannabis based medicines
- Describe the evidence for and role of cannabis based medicines in management of pain
This event attracts 2 CPD points